CD22 and leukemia: To delve deeper into leukemia cell proliferation post-injection, we noted that the percentage of CD19 or CD22 positive peripheral blood (PB) cells following CD19-CD22 CAR-T treatment was markedly lower than in other groups (Fig. 2D, E).